* If you want to update the article please login/register
Patients with shoulder pains will be tested at baseline with glenohumeral cartilage strain MRI technique, pre and post exercise. Patient reported findings including Western Ontario Shoulder Instability Index, American Shoulder and Elbow Surgeon Score, and PROMIS physical function and pain ratings will all be assessed.
Source link: https://clinicaltrials.gov/ct2/show/NCT05431114
Parkinson's Disease is a chronic, progressive, degenerative movement disorder characterized by motor and non-motor studies, and the prevalence increases with age. Although the incidence of PD rises with age, early onset can also be seen in genetic variants. At the age of 65, the incidence of PD is 1% and at 85 percent at the age of 85 years. There are various techniques for evaluating articular cartilage. In addition to these results, secondary motor signs such as bradymymia, dysarthria, and arm movement may accompany the disease during its course. Although conventional radiography is the most commonly used technique today, it is ineffective to determine cartilage thickness. Ultrasonography has been recognized as a cost-effective treatment for physicians dealing with musculoskeletal disorders, provides simultaneous imaging, and allows repeat dynamic assessments of various structures. In vivo and vitro studies have also shown that sagittal and axial measurements of femoral cartilage thickness using U. S. measurements are reliable. Ostearthritis is the most common disease related to cartilage loss in the literature. The purpose of this research is to investigate the effect of cartilage thickness in the United States on disease stage, motor function, balance, and fall risks in individuals with Parkinson's Disease.
Source link: https://clinicaltrials.gov/ct2/show/NCT05424848
Object: This research is to determine whether pharmacologic doses of the drug probenecid significantly reduced ATP and inorganic pyrophosphate levels in patients with calcium pyrophosphate deposition disease. Patients with this disease have elevated synovial fluid ATP levels, and these elevated calcium pyrophosphate crystal formation leads to acute and chronic arthritis. Probenecid vs. no drug in patients with joint effusion and known CPPD. Methodology: A 20% chance of seeing a 20% change in ATP levels in the treatment group resulted in a sample size of 20 patients in each group. Patients with definite CPPD and a joint infection will have an arthrocentesis to drain 2 ml of synovial fluid from their joint.
Source link: https://clinicaltrials.gov/ct2/show/NCT02243631
The senolytic fistinine senolytic supplement improves inflammatory and catabolic cartilage responses, which can clinically reduce OA pain while also slowing progressive cartilage deposition. Patients with mild to moderate knee OA will be evaluated at baseline and three months to see if two different fisetin dosing regimens reduce pain and function, evaluate progress in senescent cell function, and biomarkers of cartilage degradation among different fisetin dosing regimens and placebo, as well as assess acceptability and feasibility of two fisetin dosing regimens.
Source link: https://clinicaltrials.gov/ct2/show/NCT04770064
The concave portion of the septum's cartilage will be cut off, leaving an L-strut of dorsal and caudal cartilage, which will be sutured with three or four stitches. Both sides of the hemitransfixion incision will be used with 5-0 Vicryl Internal nasal splint and anterior nasal pack will be used in both directions. If there is an excess cartilage portion, it will be removed and sutured, and the graft will be sutured.
Source link: https://clinicaltrials.gov/ct2/show/NCT04579042
Aim: The aim of the investigation was to examine the connection between femoral cartilage thickness and inflammatory variables, pain intensity, and function in participants with Knee Osteoarthritis. The study was conducted in accordance with the inclusion criteria, which included 90 participants aged between 50-65 years with knee osteoarthritis and at least 50 participants without any symptom of knee OA. Both groups will be analyzed to determine the relationship between femoral cartilage thickness and inflammatory parameters, pain severity, and function in knee osteoarthritis knee osteoarthritis.
Source link: https://clinicaltrials.gov/ct2/show/NCT05456711
Patients with BMAC or Microfracture will be randomized to Hyalofastou00ae therapy. HYAFF-11'u00ae, a benzyl ester of hyaluronic acid, is a sterile, biodegradable non-woven pad made of Hyalofastu00ae. The Hyalofastu00ae compound acts as a biodegradable precursor for the autologous bone marrow aspirate concentrate. The Hyalofastu00ae is soft and elastic, and it can be cut to suit the lesion size. During the Index Procedure, autologous bone marrow is extracted from the patient intraoperatively. Using the SmartPrep 2 Bone Marrow Processing Pack, approximately 60 mL of bone marrow will be extracted from the subject's iliac crest. Concentrate concentrates, which will be concentrated via the SmartPrep BMAC 2 Centrifuge System at point of care, to produce 7 mL of bone marrow aspirate concentrate. BMAC is implanted in either a standard knee arthroscopy or min-arthrotomy depending on surgeon preference and intra-operative findings. The defect will be sized, and Hyalofastu00ae will be cut to fit the lesion area. BMAC will be loaded with Perfectofastu00ae scaffold and then implanted to cover the defect. With BMAC, the applicant is quickly adheres to the site of application, but an FDA-approved fibrin glue can be applied to the defect margins. At follow-ups, measures to monitor effectiveness will be carried out, with the primary effectiveness endpoint evaluation conducted at the 24 month time point. For analysis of treatment effects, the one-month MRI will be used as the baseline MRI.
Source link: https://clinicaltrials.gov/ct2/show/NCT02659215
* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions